Characterization of response to atezolizumab plus bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial

Salem, R; Li, DN; Sommer, N; Hernandez, S; Verret, W; Ding, BY; Lencioni, R

Salem, R (corresponding author), Northwestern Univ, Dept Radiol, Feinberg Sch Med, 676 N St Clair,Suite 800, Chicago, IL 60611 USA.

CANCER MEDICINE, 2021; 10 (16): 5437

Abstract

Background IMbrave150 is a phase III trial that assessed atezolizumab + bevacizumab (ATEZO/BEV) versus sorafenib (SOR) in patients with unresectable h......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索